Naloxone SprayMarketwas valued at USD 0.32 Billion in 2021 and is projected to reach USD 1.94 Billion by 2028, growing at a Compound Annual Growth Rate (CAGR) of 20.1% during 2022-2028. Naloxone is able to restore normal breathing to a person whose breathing has stopped or decreased due to opioid or heroin overdose. Currently, opioid abuse is one of the leading causes of drug overdose and the leading cause of death worldwide. However, it is more common in North America and Europe.
Opioid problems in the US have reached the epidemic, resulting in significant healthcare costs and loss of resources. The excessive demand for better treatment and opioid-dependent individuals is leading to the growth of the Naloxone Spray in the United States. Opioid dependence is a major problem worldwide, with more than 25 million people affected. The problem exists in both developed and developing countries. Heroin is the most abused opioid in the world outside the US when over-the-counter opioid painkillers lead to overdose and overuse. As part of emergency treatment, naloxone nasal spray is used to reverse the life-threatening effects of opiate or opioid overdose. All of these factors act as drivers of the global Naloxone Spray. Opioids include drugs such as morphine, fentanyl, and tramadol used to treat pain. However, because of their pharmacological effects, their non-medical use, long-term use, misuse, and non-medical use can lead to opioid dependence and can cause respiratory distress, or even lead to death or other health problems. The price of naloxone rises and acts as a barrier to reducing the number of deaths caused by opioid overdose. In the United States, the effects of skyrocketing prices are reduced by the support programs and free sales of naloxone through community-based organizations or public health programs.
The Naloxone Spray Market can be segmented upon the mode of its administration such as nasal, oral, and injectables. The Naloxone Spray consists of sale of Naloxone Spray by organizations, sole traders, and affiliates. The product is pre-filled with naloxone, and the needle-free device is sprayed in one nostril, and does not need to be combined. It is used to treat opioid emergencies with symptoms such as respiratory problems and difficulty sleeping or inability to respond. The Naloxone Spray market consists of distribution channels such as hospitals, clinics, retailers, online pharmacies, among others.
Major players in the Global Naloxone Spray Market include Emergent BioSolutions (US), Pfizer (US), Teva Pharmaceutical Industries Ltd. (Israel), Opiant Pharmaceuticals (US), Hikma Pharmaceuticals (UK), Nasus Pharma (Israel), Amphastar Pharmaceuticals (US), Indivior PLC (US), Samarth Pharma Pvt. Ltd. (India), Troikaa Pharmaceuticals Ltd. (India), and Neon Laboratories Limited (India)..